Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.42 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15265664 | 1.00 | NR1H2 (0.46) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL958699 | 1.00 | NR1H2 (0.46) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1279779 | 1.00 | NR1H2 (0.46) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1279783 | 1.00 | NR1H2 (0.46) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1059992 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1059994 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL2546915 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1059077 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL585825 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 | |
| SCHEMBL1059075 | 0.91 | GPR119 (0.45) | NR1H2GPR119DPP4HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141483-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-9000191-B2 | Serotonin reuptake inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-8969403-B2 | Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2627630-B1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8853255-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140243536-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2456436-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8729119-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140121385-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | THERAVANCE, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8658691-B2 | Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound | THERAVANCE, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8471040-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8455665-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130085172-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-04-04 | — | — | US | disclosed |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273786-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2456436-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2011011231-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | NR1H2 3591/4885GPR119 1219/4885DPP4 1381/4885 |
| US-20150141483-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | PKD1, PKD2, PYCR1 | NR1H2 2266/4885GPR119 2438/4885DPP4 112/4885 |
| US-20140121385-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | PKD1, PKD2, PYCR1 | NR1H2 2266/4885GPR119 2438/4885DPP4 112/4885 |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | NR1H2 1739/4885GPR119 628/4885DPP4 1987/4885 |
| US-20140243536-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | NR1H2 1739/4885GPR119 628/4885DPP4 1987/4885 |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | NR1H2 3591/4885GPR119 1219/4885DPP4 1381/4885 |
| US-20130085172-A1 | CRYSTALLINE FORMS OF A 3-[2-METHANESULFONYL-1-(4-TRIFLUOROMETHYL-PHENOXY)ETHYL]PYRROLIDINE COMPOUND | PKD1, PKD2, PYCR1 | NR1H2 2266/4885GPR119 2438/4885DPP4 112/4885 |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | NR1H2 3591/4885GPR119 1219/4885DPP4 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.